{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:27:55Z","timestamp":1788834475359,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11523-020-00744-8","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T14:07:43Z","timestamp":1596463663000},"page":"673-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-994X","authenticated-orcid":false,"given":"Tomas","family":"Buchler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kopecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anezka","family":"Zemankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Wiesnerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Streckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Rozsypalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Poprach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"744_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing. 2010;39:412\u201323. https:\/\/doi.org\/10.1093\/ageing\/afq034.","journal-title":"Age Ageing."},{"key":"744_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169.","journal-title":"Age Ageing."},{"key":"744_CR3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539\u201347. https:\/\/doi.org\/10.1200\/JCO.2012.45.2722.","journal-title":"J Clin Oncol."},{"key":"744_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CMM Prado","year":"2008","unstructured":"Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(08)70153-0.","journal-title":"Lancet Oncol."},{"key":"744_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2008;33:997\u20131006. https:\/\/doi.org\/10.1139\/H08-075.","journal-title":"Appl Physiol Nutr Metab Physiol Appl Nutr Metab."},{"key":"744_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcsm.12337","volume":"9","author":"SA Kurk","year":"2018","unstructured":"Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, et al. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2018;9:909\u201319. https:\/\/doi.org\/10.1002\/jcsm.12337.","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"744_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02080-4","author":"A Gokyer","year":"2019","unstructured":"Gokyer A, Kucukarda A, Kostek O, Hacioglu MB, Sunal BS, Demircan NC, et al. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib. Clin Transl Oncol. 2019. https:\/\/doi.org\/10.1007\/s12094-019-02080-4.","journal-title":"Clin Transl Oncol."},{"key":"744_CR8","doi-asserted-by":"publisher","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","volume":"7","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Blanchet B, Durand J-P, Boudou-Rouquette P, Michels J, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:e37563. https:\/\/doi.org\/10.1371\/journal.pone.0037563.","journal-title":"PLoS One."},{"key":"744_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/bjc.2013.58","volume":"108","author":"O Huillard","year":"2013","unstructured":"Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108:1034\u201341. https:\/\/doi.org\/10.1038\/bjc.2013.58.","journal-title":"Br J Cancer."},{"key":"744_CR10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","volume":"21","author":"S Antoun","year":"2010","unstructured":"Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21:1594\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdp605.","journal-title":"Ann Oncol."},{"key":"744_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/COC.0000000000000061","volume":"40","author":"SJ Cushen","year":"2017","unstructured":"Cushen SJ, Power DG, Teo MY, MacEneaney P, Maher MM, McDermott R, et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol. 2017;40:47\u201352. https:\/\/doi.org\/10.1097\/COC.0000000000000061.","journal-title":"Am J Clin Oncol."},{"key":"744_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11523-016-0430-0","volume":"11","author":"H Ishihara","year":"2016","unstructured":"Ishihara H, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, et al. Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. Target Oncol. 2016;11:605\u201317. https:\/\/doi.org\/10.1007\/s11523-016-0430-0.","journal-title":"Target Oncol."},{"key":"744_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917\u201327. https:\/\/doi.org\/10.1016\/S1470-2045(16)30107-3.","journal-title":"Lancet Oncol."},{"key":"744_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591\u20137. https:\/\/doi.org\/10.1200\/JCO.2016.70.7398.","journal-title":"J Clin Oncol."},{"key":"744_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/0148607115604149","volume":"40","author":"SL Gomez-Perez","year":"2016","unstructured":"Gomez-Perez SL, Haus JM, Sheean P, Patel B, Mar W, Chaudhry V, et al. Measuring abdominal circumference and skeletal muscle from a single cross-sectional computed tomography image: a step-by-step guide for clinicians using National Institutes of Health ImageJ. J Parenter Enteral Nutr. 2016;40:308\u201318. https:\/\/doi.org\/10.1177\/0148607115604149.","journal-title":"J Parenter Enteral Nutr."},{"key":"744_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol."},{"key":"744_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0286-9","author":"A Poprach","year":"2012","unstructured":"Poprach A, Bortl\u00ed\u010dek Z, B\u00fcchler T, Melichar B, Lakom\u00fd R, Vyzula R, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol. 2012. https:\/\/doi.org\/10.1007\/s12032-012-0286-9.","journal-title":"Med Oncol."},{"key":"744_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1113\/jphysiol.2008.164384","volume":"587","author":"IM Olfert","year":"2009","unstructured":"Olfert IM, Howlett RA, Tang K, Dalton ND, Gu Y, Peterson KL, et al. Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice. J Physiol. 2009;587:1755\u201367. https:\/\/doi.org\/10.1113\/jphysiol.2008.164384.","journal-title":"J Physiol."},{"key":"744_CR19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1242\/dev.126.8.1621","volume":"126","author":"S Dietrich","year":"1999","unstructured":"Dietrich S, Abou-Rebyeh F, Brohmann H, Bladt F, Sonnenberg-Riethmacher E, Yamaai T, et al. The role of SF\/HGF and c-Met in the development of skeletal muscle. Development. 1999;126:1621\u20139.","journal-title":"Development."},{"key":"744_CR20","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1074\/jbc.M610916200","volume":"282","author":"T Crepaldi","year":"2007","unstructured":"Crepaldi T, Bersani F, Scuoppo C, Accornero P, Prunotto C, Taulli R, et al. Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem. 2007;282:6812\u201322. https:\/\/doi.org\/10.1074\/jbc.M610916200.","journal-title":"J Biol Chem."},{"key":"744_CR21","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1510016.","journal-title":"N Engl J Med."},{"key":"744_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.012.","journal-title":"Eur J Cancer."},{"key":"744_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11523-018-0600-3","volume":"13","author":"H Ishihara","year":"2018","unstructured":"Ishihara H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J, et al. Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. Target Oncol. 2018;13:745\u201355. https:\/\/doi.org\/10.1007\/s11523-018-0600-3.","journal-title":"Target Oncol."},{"key":"744_CR24","first-page":"mdz249-063","volume":"30","author":"CAC Silva","year":"2019","unstructured":"Silva CAC, Afonso D, Colomba E, Le Teuff G, Derosa L, Raynard B, et al. 967P Skeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma. Ann Oncol. 2019;30:mdz249-063.","journal-title":"Ann Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-020-00744-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:16:54Z","timestamp":1627946214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-020-00744-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00744-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"3 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tomas Buchler received honoraria for advisory boards and\/or lectures from Ipsen, Bristol-Myers Squibb, Amgen, Novartis, Pfizer, and Roche. Bohuslav Melichar received honoraria for advisory boards and\/or lectures from Novartis, Pfizer, Glaxo Smith Kline, Roche, Astellas, Bristol Myers Squibb and Bayer. Alexandr Poprach received honoraria for lectures from Novartis, Bristol-Myers Squibb, Roche and Bayer. Anezka Zemankova received honoraria for lecture from Bristol-Myers Squibb. Igor Richter received honoraria for lectures from Ipsen. The other authors have declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The present study was a retrospective sub-study of the RENIS registry project which is approved by the Ethics Committee of the Brno University Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study design: Tomas Buchler. Data acquisition: Tomas Buchler, Marie Kopecka, Anezka Zemankova, Eva Streckova, Aneta Rozsypalova, Bohuslav Melichar, Alexandr Poprach, Igor Richter. Statistical analysis: Marketa Wiesnerova, Tomas Buchler. Manuscript preparation: Tomas Buchler. All authors reviewed and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}